We found for
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
